FIELD: medicine.
SUBSTANCE: what is presented is using a combination containing an effective amount of an antibody neutralizing human NKG2A, and an antibody neutralizing human PD-L1, in treating cancer and in modulating NKG2A+ PD-1+ CD8+ T-cells in an individual. Disclosed is a pharmaceutical composition for treating cancer in a human patient. Disclosed are kits for treating cancer in a human patient. A method of activating NKG2A+/PD1+ CD8+ T-cells in an individual, a method of in vitro modulating the activity of NKG2A+ PD-1+ CD8+ T-cells and methods of treating or preventing cancer in an individual are disclosed.
EFFECT: presented group of inventions provides a synergetic effect of introducing an antibody neutralizing human NKG2A, and an antibody which neutralises human PD-L1.
43 cl, 5 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORY PATHWAY NEUTRALIZATION IN LYMPHOCYTES | 2017 |
|
RU2769569C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| CD30XCD16 ANTIBODY COMBINATION FOR THERAPY WITH PD-1 ANTAGONIST | 2016 |
|
RU2761352C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| NK-CELL ACTIVATING FUSED PROTEIN, NK-CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2018 |
|
RU2740438C1 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
